Search Result

Results for "

BTK Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (153) Antibiotic (1) Apoptosis (10) Autophagy (1) BCRP (1) BMX Kinase (2) c-Met/HGFR (1) CDK (1) Cytochrome P450 (2) Dengue virus (2) Drug Metabolite (2) EGFR (6) Flavivirus (2) FLT3 (2) Glutathione S-transferase (1) Isotope-Labeled Compounds (3) Itk (4) JAK (11) Ligands for Target Protein for PROTAC (4) MALT1 (1) MNK (1) Molecular Glues (1) Nuclear Factor of activated T Cells (NFAT) (1) PI3K (1) Polo-like Kinase (PLK) (2) PROTACs (9) Pyroptosis (1) RANKL/RANK (1) RET (1) Src (2) Toll-like Receptor (TLR) (1) Topoisomerase (1)
By Research Areas:	Cancer (112) Cardiovascular Disease (3) Endocrinology (1) Infection (5) Inflammation/Immunology (60) Metabolic Disease (4) Neurological Disease (5)
Click Chemistry:	Azide (1)

165

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Btk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131705

BTK inhibitor 17	Btk	Inflammation/Immunology
BTK inhibitor 17 is a potent and orally active irreversible *BTK* inhibitor with an IC₅₀ of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research .

HY-125997

BTK inhibitor 10	Btk	Inflammation/Immunology
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .

HY-101766

Btk inhibitor 2 BGB-3111 analog	Btk	Inflammation/Immunology
Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.

HY-128403

BTK inhibitor 8	Btk	Inflammation/Immunology
BTK inhibitor 8 (Compound 27) is a *Btk* inhibitor with an IC₅₀ of 0.11 nM. BTK inhibitor 8 inhibits B cell activation in hWB with an IC₅₀ of 2 nM .

HY-132196

BTK inhibitor 18	Btk	Inflammation/Immunology
BTK inhibitor 18 is a potent, selective,orally active and covalent *Btk* inhibitor with a IC₅₀ of 142 nM. BTK inhibitor 18 has anti-inflammatory activities .

HY-143730

BTK inhibitor 20	Btk	Cancer
BTK inhibitor 20 is a potent *BTK* inhibitor with an IC₅₀ of 8 nM .

HY-139881

BTK inhibitor 19	Btk	Cancer
BTK inhibitor 19 is a highly selective, covalent *BTK* inhibitor (IC₅₀ = 2.7 nM).

HY-130255

BTK inhibitor 13	Btk	Inflammation/Immunology
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM .

HY-160167

BTK-IN-30	Btk	Inflammation/Immunology
BTK-IN-30 (compound cpd15) is an inhibitor of Bruton's Tyrosine Kinase (BTK) and mutant BTK with IC₅₀ values of 6.72 and 6.11nM respectively .

HY-162257

BTK-IN-34	Btk	Cancer
BTK-IN-34 (compound 9h) is a selective *BTK* inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .

HY-145373

BMS-986143	Btk	Inflammation/Immunology
BMS-986143 is an orally active, reversible *BTK* inhibitor with an IC₅₀ of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC₅₀s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .

HY-153705

BTK-IN-25	Btk	Cancer
BTK-IN-25 (compound 71) is a potent inhibitor of *BTK, and inhibits* BTK(C481S) with an IC₅₀ value of 0.77 nM. BTK-IN-25 inhibits BTK in DOHH2 cells with an IC₅₀ value of 1 nM .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of *BTK. BTK-IN-32 activates full-length BTK* and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-150752

BTK-IN-15	Btk Pyroptosis	Cancer
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits *BTK* with an IC₅₀ value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .

HY-141689

BTK-IN-3	Btk	Cancer
BTK-IN-3 (example 1) is an inhibitor of *BTK. BTK*-IN-3 can used to study cancer .

HY-160141

BTK-IN-29	Btk	Cancer
BTK-IN-29 (compound 14) is an inhibitor of *Btk* .

HY-157159

BTK-IN-28	Btk	Cancer
BTK-IN-28 (compound PID-4) is a potent *BTK* inhibitor with anticancer activity. BTK-IN-28 has inhibitory effects on BTK and downstream signaling cascades and selectively inhibits Burkitt lymphoma RAMOS proliferation. BTK-IN-28 has no significant cytotoxicity towards non-tumor cells .

HY-147580

BTK-IN-10	Btk	Cancer
BTK-IN-10 is a potent *BTK* inhibitor with IC₅₀s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111) .

HY-152201

BTK-IN-18	Btk	Cancer
BTK-IN-18 is a potent, reversible *BTK* inhibitor with an IC₅₀ of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo .

HY-101521

CHMFL-BTK-01	Btk	Cancer
CHMFL-BTK-01 (compound 9) is a highly selective irreversible *BTK* inhibitor, with an IC₅₀ of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation .

HY-147582

BTK-IN-12	Btk	Cancer
BTK-IN-12 is a potent *BTK* inhibitor with IC₅₀s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8) .

HY-158064

BTK-IN-36	Btk	Cancer
BTK-IN-36 (S-016) is a *BTK* inhibitor, with IC₅₀ of 0.5 nM. BTK-IN-36 can be used in cancer-related research .

HY-169307

BTK-IN-38	Btk	Cancer
BTK-IN-38 (Example 125) is a potent *BTK* inhibitor. BTK-IN-38 inhibits DOHH2 and BT474 cells proliferation with IC₅₀s of 114 and 340 nM, respectively .

HY-153951S

BTK-IN-26	Btk	Inflammation/Immunology Cancer
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-159589

BTK-IN-37	Btk Apoptosis	Cancer
BTK-IN-37 (compound 8d) is a *BTK* inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with K_i and IC₅₀ of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .

HY-148585

BTK-IN-22	Btk	Cancer
BTK-IN-22 is a *BTK* inhibitor (IC₅₀: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC₅₀s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)

HY-148594

BTK-IN-23	Btk	Cancer
BTK-IN-23 is a *BTK* inhibitor (IC₅₀: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC₅₀s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .

HY-101941

BTK IN-1 SNS062 analog	Btk	Inflammation/Immunology Cancer
BTK IN-1 (SNS062 analog) is a potent *BTK* inhibitor, with an IC₅₀ of <100 nM.

HY-143717

JAK3/BTK-IN-2	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-2 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)

HY-143720

JAK3/BTK-IN-5	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-5 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, example 35)

HY-143716

JAK3/BTK-IN-1	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-1 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002) .

HY-143718

JAK3/BTK-IN-3	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-3 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)

HY-143719

JAK3/BTK-IN-4	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-4 is a potent inhibitor of *JAK3/BTK*. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)

HY-152212

BTK-IN-19	Btk	Inflammation/Immunology
BTK-IN-19 (Compound 51) is a reversible *BTK* inhibitor with an IC₅₀ of <0.001 μM .

HY-160219S

BTK-IN-33	Btk	Cancer
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-156553

BTK-IN-27	Btk	Inflammation/Immunology Cancer
BTK-IN-27 (example 8) is a *BTK* inhibitor (IC₅₀: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC₅₀: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .

HY-115876

BTK-IN-5	Btk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
BTK-IN-5 is a covalent *BTK* inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

HY-151211

BTK-IN-16	Btk	Inflammation/Immunology Cancer
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .

HY-151920

BTK-IN-17	Btk	Inflammation/Immunology
BTK-IN-17 (compound 36R) is a selective and orally activeBTK inhibitor with an IC₅₀ value of 13.7 nM. BTK-IN-17 decreases the expression of p-BTK ^Y223 and p-PLCγ2 ^Y1217. BTK-IN-17 shows anti-inflammatory effects .

HY-163183

JAK3/BTK-IN-7	JAK Btk	Inflammation/Immunology
JAK3/BTK-IN-7 (XL-12) is a *JAK3/BTK* inhibitor with IC₅₀ values of 2 nM and 14 nM, respectively. JAK3/BTK-IN-7 has anti-inflammatory activity and can be used in the study of rheumatoid arthritis .

HY-115944

BTK-IN-9	Btk Apoptosis	Inflammation/Immunology Cancer
BTK-IN-9 is a reversible *BTK* inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells .

HY-148832

BTK-IN-20	Btk	Inflammation/Immunology Cancer
BTK-IN-20 (compound 283) is a *BTK* tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .

HY-162280

PROTAC BTK Degrader-9	PROTACs RANKL/RANK Nuclear Factor of activated T Cells (NFAT) Btk	Cancer
PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca ²⁺-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model .

HY-10644

*Lck inhibitor* 2**	Src	Inflammation/Immunology
Lck inhibitor 2 is a multi-target tyrosine kinase inhibitor with IC50s of 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively.

HY-130983

N-piperidine Ibrutinib hydrochloride	Btk Ligands for Target Protein for PROTAC	Cancer
N-piperidine Ibrutinib hydrochloride (Compound 1) is a reversible Ibrutinib derivative. N-piperidine Ibrutinib hydrochloride is a potent *BTK* inhibitor with IC₅₀s of 51.0 and 30.7 nM for WT BTK and C481S BTK, respectively . N-piperidine Ibrutinib hydrochloride can be used as a BTK ligand in the synthesis of a series of PROTACs, such as SJF620 (HY-133137). SJF620 is a potent PROTAC BTK degrader with a DC₅₀ of 7.9 nM .

HY-112215

Nemtabrutinib 2 Publications Verification ARQ-531; MK-1026	Btk	Inflammation/Immunology Cancer
ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC₅₀s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

HY-131328

Pirtobrutinib 2 Publications Verification LOXO-305	Btk	Cancer
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation *BTK* inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .

HY-143900

BTK-IN-7	Btk Apoptosis	Inflammation/Immunology Cancer
BTK-IN-7 is a potent and selective inhibitor of *BTK* (IC₅₀=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of *BTK. BTK* plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-129390

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

2,689 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 2,689 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L016

Protein Tyrosine Kinase Compound Library

1,064 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,064 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L129

Target Protein Ligand Library

37 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 37 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent *BTK, JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-110013

Terreic acid	Microorganisms Source classification	Btk Antibiotic
Terreic acid, a quinone epoxide antibiotic, acts as an effective *Btk* inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM .

Cat. No.	Product Name	Chemical Structure

HY-10997S

Ibrutinib-d5
Ibrutinib-d₅ is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor[1].

HY-101474S

Zanubrutinib-d5
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor[1].

HY-17600S

Acalabrutinib-d4
Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1]. Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-160219S

BTK-IN-33
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-101474BS

(R)-Zanubrutinib-d5
(R)-Zanubrutinib-d₅ is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-135334S

ACP-5862-d4

ACP-5862-d₄ is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM[1][2].

Cat. No.	Product Name		Classification